Novo Nordisk says CagriSema outperformed Lilly’s Zepbound in Phase 3
Novo Nordisk said its CagriSema (cagrilintide plus semaglutide) at 1 mg each achieved greater weight loss than Eli Lilly’s Zepbound in a Phase 3 trial, reporting 12.4% weight loss.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.